Skip to main content
. 2020 Nov 8;10(11):276. doi: 10.3390/life10110276

Figure 4.

Figure 4

Association between CIN70 and immune checkpoint inhibitor responses. (A) CIN70 among responders and non-responders in the Hugo et al. melanoma cohort (p-value = 0.226, Mann–Whitney U test). (B) CIN70 among responders and non-responders in the Snyder et al. urothelial cancer cohort (p-value = 0.108, Mann-Whitney U test). (C) Survival analysis comparing OS of patients with high/low CIN70 score in the Hugo et al. melanoma cohort (p-value = 0.106, log-rank test). (D) Survival analysis comparing OS of patients with high/low CIN70 score in the Snyder et al. urothelial cancer cohort (p-value = 0.222, log-rank test). DCB: durable clinical benefit, NDB: no durable benefit.